{"id":"trabodenoson-3-0-qd","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Eye pain"},{"rate":"5-10%","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL3648127","moleculeType":"Small molecule","molecularWeight":"431.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating the adenosine A1 receptor, trabodenoson is thought to reduce intraocular pressure in patients with glaucoma. This is achieved through a decrease in aqueous humor production and an increase in uveoscleral outflow.","oneSentence":"Trabodenoson is a selective adenosine A1 receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:36.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of glaucoma"}]},"trialDetails":[{"nctId":"NCT02829996","phase":"PHASE2","title":"Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2016-08-19","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":201},{"nctId":"NCT02565173","phase":"PHASE3","title":"Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2015-09","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INO-8875"],"phase":"phase_3","status":"active","brandName":"trabodenoson 3.0% QD","genericName":"trabodenoson 3.0% QD","companyName":"Inotek Pharmaceuticals Corporation","companyId":"inotek-pharmaceuticals-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trabodenoson 3.0% is being studied as a potential treatment for Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT) in combination with latanoprost. The exact mechanism of trabodenoson is not specified in the provided information, but it is being investigated in a fixed-dose combination with latanoprost in a Phase II clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}